Alembic Pharmaceuticals stated that the United States Food and Drug Administration (US FDA) had conducted an inspection at the company's bioequivalence facility located at Vadodara from 3rd to 7th of ...

Drug firm Alembic Pharmaceuticals Ltd on Friday (March 7) announced the completion of a scheduled inspection by the United States Food and Drug Administration (FDA) at its bioequivalence facility in ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

The recovery witnessed by the Nifty and Sensex needs a proper analysis. Is it simply a short-covering rally? Or is it a relief rally because the street has been witnessing a decline for the past many ...

Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in medications like Ozempic, Rybelsus, ...

Tirzepatide (Mounjaro) has had a remarkable journey to prominence since its UK marketing authorisation in 2023.1 Approved for glycaemic control in type 2 diabetes and weight management in people who ...

Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web ...

The active ingredient in Mounjaro is tirzepatide. Zepbound also contains tirzepatide and is FDA approved for weight loss and weight management. Tirzepatide works by imitating the effects of ...

Mounjaro (tirzepatide) is a brand-name injection prescribed for type 2 diabetes in adults. As with other drugs, Mounjaro can cause side effects, such as nausea, diarrhea, and appetite loss.

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

Semaglutide follows rival GLP-1RA tirzepatide in making it off the FDA’s shortage list. Eli Lilly’s Ozempic and Mounjaro, of which tirzepatide is the active ingredient, was removed from the list in ...